论文部分内容阅读
目的:探讨唑来膦酸联合TEC化疗方案治疗乳腺癌骨转移的临床价值。方法:将2010年6月至2012年6月武汉市汉口医院收治的66例乳腺癌多发性骨转移患者随机分为化疗组(TEC)18例、唑来膦酸组22例、联合组(唑来膦酸+TEC)26例,观察VAS评分和ECOG评分变化,评估骨转移病灶疗效。结果:唑来膦酸组与联合组VAS评分对基线变化的百分比比较。差异有统计学意义(P<0.05)。联合组镇痛药使用比例低于唑来磷酸组和化疗组(P<0.05)。化疗组、唑来膦酸组、联合组骨转移灶的缓解有效率分别是16.7%、31.8%、57.7%,联合组明显高于化疗组和唑来膦酸组(P<0.05)。结论:唑来磷酸联合TEC化疗治疗乳腺癌骨转移的疗效明显优于单纯TEC化疗和唑来磷酸治疗。
Objective: To investigate the clinical value of zoledronic acid combined with chemotherapy regimen in the treatment of breast cancer bone metastases. Methods: Sixty-six patients with multiple bone metastases of breast cancer admitted from June 2010 to June 2012 in Wuhan Hankou Hospital were randomly divided into chemotherapy group (TEC) 18 cases, zoledronic acid group 22 cases, combination group 26 cases of phosphonic acid + TEC), VAS score and ECOG score changes were observed to assess the efficacy of bone metastases. Results: The percentage change of baseline VAS score between zoledronic acid group and combination group was compared. The difference was statistically significant (P <0.05). Analgesic use in the combination group was lower than that in the zoledronic acid and chemotherapy groups (P <0.05). The effective rates of chemotherapy, zoledronic acid and combined bone metastases were 16.7%, 31.8% and 57.7%, respectively. The combined group was significantly higher than the chemotherapy group and the zoledronic acid group (P <0.05). Conclusion: The efficacy of zoledronic acid combined with TEC chemotherapy in the treatment of breast cancer with bone metastases is significantly better than that of chemotherapy alone and zoledronic acid alone.